Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease
Cognition Therapeutics (NASDAQ: CGTX) has received a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research. This funding will support preclinical studies of two sigma-2 receptor modulators in animal models of Parkinson's disease, led by VP of research Mary E. Hamby, Ph.D. The studies aim to develop disease-modifying therapies for Parkinson's, where current options are lacking. CEO Anthony Caggiano emphasized the potential of σ-2 receptor targeting to impact disease progression biomarkers.
- Awarded a grant from The Michael J. Fox Foundation for research on sigma-2 receptor modulators.
- Potential to develop disease-modifying therapies for Parkinson's disease.
- None.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, today announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). This grant will fund preclinical studies of two sigma-2 (σ-2) receptor modulators in animal models of Parkinson’s disease that will be led by Cognition Therapeutics’ VP of research, Mary E. Hamby, Ph.D.
“There is a need to discover and develop novel therapeutics for Parkinson’s disease, for which no disease-modifying therapies exist,” explained Anthony Caggiano, M.D., Ph.D., Cognition Therapeutics’ chief medical officer. “Targeting the σ-2 receptor for Parkinson’s disease is a promising, potentially disease-modifying therapeutic approach. We intend to investigate two σ-2 receptor modulators in our research pipeline to determine their impact on biomarkers of disease progression. If successful, these studies would provide proof of concept to support the subsequent clinical development of a σ-2 modulator for the treatment of Parkinson’s disease.”
Parkinson’s disease and other synucleinopathies such as dementia with Lewy bodies (DLB) are associated with a build-up of α-synuclein oligomers that bind to neurons where they impair critical cellular processes, causing synaptic dysfunction and eventual loss. Published in vitro studies conducted by Cognition scientists found that the binding and internalization of α-synuclein oligomers in cultured neurons was inhibited by the addition of a σ-2 receptor antagonist (Limegrover et al, 2021). The studies supported by this MJFF Therapeutic Pipeline Program grant will seek to confirm and build upon the findings from Cognition’s earlier preclinical research.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the sigma-2 (σ-2) receptor, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the σ-2 receptor complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. Additional information about Cognition and its product candidates may be found online at www.cogrx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Information:
Cognition Therapeutics, Inc.
info@cogrx.com
Aline Sherwood (media)
Scienta Communications
asherwood@scientapr.com
Lisa Sher (investors)
Tiberend Strategic Advisors
lsher@tiberend.com
FAQ
What grant did Cognition Therapeutics receive?
What research will the grant fund?
Who is leading the studies funded by the grant?
What is the goal of the research funded by the grant?
What does the sigma-2 receptor target for Parkinson's disease?
